Lidia Fonseca is Executive Vice President, Chief Digital and Technology Officer at Pfizer, responsible for developing and implementing an enterprise-wide digital strategy. Lidia leads all digital, data and technology solutions across the company. She is also responsible for Pfizer Learning and Development and Business Process Excellence.
She spearheads several transformational programs and initiatives to support Pfizer’s purpose of delivering Breakthroughs that Change Patients’ Lives, applying digital capabilities and products including digitizing drug discovery and development; improving health outcomes and patient experiences; improving operational processes through automation and robotics; and delivering powerful insights with data, advanced analytics, and artificial intelligence (AI) for better decision-making.
Lidia led the Digital team in Pfizer’s critical efforts to help accelerate the development of a COVID-19 vaccine in less than one year, as well as the oral antiviral treatment, driving innovations across the entire value chain from research, to the clinical trial, to manufacturing and patient engagement.
Lidia led the effort to create Pfizer’s Advanced Analytics AI Platform that brings together data from Pfizer and external partners as well as tools to model scientific and clinical decisions, patterns and insights. She is also driving initiatives to re-imagine clinical trials through robotics/automation and tech-enabled processes that enhance patient, provider and site experiences, improve selection and recruitment, and reduce clinical trial cycle times.
Lidia spearheaded the launch of Pfizer’s Digital Companion™, a suite of digital products and solutions to deepen engagement between patients and physicians for better outcomes. She collaborated to deliver the following: Mabu® Wellness Coach for patients (Mabu® is a registered trademark of Catalia Health Inc.), Champix Chatbot to assist with smoking cessation, LivingWith™ app to support patients undergoing cancer treatment and their loved ones, drone medicine delivery in the Dominican Republic to increase patient access to medicines in remote and difficult-to-reach locations, and a partnership with Fitbit to drive timely diagnosis of atrial fibrillation. She is also leading the effort to introduce AI-powered predictive algorithms to help disease suspicion, treatment optimization and adherence.
She also leads initiatives to empower Pfizer colleagues, simplifying and automating their work with robotics, machine learning, and predictive analytics that enable better and faster decisions, while driving efficiencies. Since 2019, Pfizer has automated 90 percent of approximately 100 million transactions across the company. In 2021, Lidia’s team launched the Pfizer Learning Academy, providing learning, training and development for all Pfizer employees.
In her prior role, Lidia was the Senior Vice President and CIO at Quest Diagnostics, the world’s leading provider of diagnostic information services serving one in three American adults each year, and half the physicians and hospitals in the U.S. She was responsible for technology, informatics and digital solutions. Lidia led the effort to create Quest's innovative Quanum Solutions brand of healthcare IT and data analytics offerings that deliver critical insights to improve quality outcomes and patient care while lowering costs.
Lidia was named to the list of 50 Most Powerful Latinas in 2020 and 2021 by the Association of Latino Professionals for America. Pfizer won the 2021 CIO 100 award for digital innovation in manufacturing. In 2020, Lidia became a member of the Fast Company Impact Council and Pfizer was named one of Fast Company magazine’s 100 Best Workplaces for Innovators, which recognizes innovation in technology, research and development, and their employees. She was also named 2020 Healthcare Influencer and 2019 Healthcare Transformer by Medical, Marketing & Media. In 2018, she was the only diagnostics provider executive to participate in the White House Artificial Intelligence Summit. She received the 2017 Forbes CIO Innovation Award that recognizes CIOs who lead revenue enhancing innovation efforts.
Lidia was a founding member of Synaptic Health Alliance, comprised of leading healthcare companies Aetna, Cognizant, Humana, MultiPlan, Optum, Quest Diagnostics and UnitedHealthcare, which uses blockchain technology to improve provider data quality and serves as a distributed partnership model to tackle other industry-wide data issues.
Lidia is a member of the Board of Directors of Tegna, Inc. (NYSE: TGNA) and the U.S.-Japan Business Council. She was previously a member of the Board of Directors at Gannet, Inc. (NYSE: GCI) from 2014-2017 and Q2 Solutions, a joint venture between Quest Diagnostics and IQVIA, from 2016 to 2018. She earned a bachelor’s degree from the University of California, Berkeley and an MBA and Master Business Informatics from Rotterdam School of Management, Erasmus Graduate School of Business. Lidia is married and has two children.